A PYMNTS Company

US: Pharma research firm may sell before IPO

By  |  August 1, 2016

Reuters has reported that buyout firms Advent International and CVC Capital Partners have made offers to acquire inVentiv Group Holdings, a pharmaceutical research firm, before the firm launches an IPO valued at $4 billion.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The bids illustrate the private equity sector’s insatiable appetite for contract research organizations such as inVentiv, which have benefited in recent years from the pharmaceutical companies’ drive to cut costs, reduce clinical trial times and expand their research and development presence around the world.

    Thomas H. Lee Partners, the private equity firm that owns inVentiv, will decide by next week whether to press ahead with an IPO for inVentiv or agree to an outright sale of the company with one of the two private equity firms.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.